Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Review, H1 2016

  • ID: 3788899
  • Drug Pipelines
  • 34 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Carna Biosciences, Inc.
  • NeuroNascent, Inc.
  • Selvita S.A.
  • MORE
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Review, H1 2016

Summary

‘Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Review, H1 2016’, provides in depth analysis on Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1)
- The report reviews Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Carna Biosciences, Inc.
  • NeuroNascent, Inc.
  • Selvita S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Overview

Therapeutics Development

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Products under Development by Stage of Development

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Products under Development by Therapy Area

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Products under Development by Indication

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Pipeline Products Glance

Early Stage Products

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Products under Development by Companies

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Products under Development by Universities/Institutes

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Companies Involved in Therapeutics Development

Carna Biosciences, Inc.

NeuroNascent, Inc.

Selvita S.A.

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Drug Profiles

Harmine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PST-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to inhibit DYRK1A for CNS Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Dormant Projects

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Discontinued Products

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) - Featured News & Press Releases

Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics

Mar 20, 2013: BIO5-TGen Collaboration Focused On Drug Development For Alzheimer’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 34List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Carna Biosciences, Inc., H1 2016

Pipeline by NeuroNascent, Inc., H1 2016

Pipeline by Selvita S.A., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 31List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Carna Biosciences, Inc.
  • NeuroNascent, Inc.
  • Selvita S.A.
  • MORE
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development.

Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Preclinical and Discovery stages are 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Our latest report Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A – Pipeline Review, H1 2016, outlays comprehensive information on the Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Carna Biosciences, Inc.
NeuroNascent, Inc.
Selvita S.A.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll